At a time when direct-to-consumer genomics companies probably don't need media reports questioning their services, a personal essay in the New York Times this week casts doubt on whether DTC tests can be trusted, or are accurate enough to be useful.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.